Clinical trials: Influenza Virus
Influenza, Human
A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine
This study is a pediatric dose-ranging study to evaluate the safety and immunogenicity of vaccination with different MF59-adjuvanted H5N1 vaccine formulations.
- Trial name
- NCT04669691
- Testing
- H5N1 antigen combined with MF59 adjuvant
- Where
- 7 sites in Estonia, Philippines
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza B
Dose, Safety, and Pathogenicity of a New Influenza B Strain
This is an exploratory study of an influenza B challenge strain to determine the optimum infectious titer of challenge agent in healthy participants 18 to 55 years of age.
- Trial name
- NCT06254820
- Testing
- influenza B/Connecticut/1/21 virus part a dose arm 1, influenza B/Connecticut/1/21 virus part a dose arm 2, influenza B/Connecticut/1/21 virus part b dose 1
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hvivo
Influenza
Post-marketing Study to Evaluate the Efficacy of Influenza Vaccine
As a result of the recent supply shortages in the U.S., as well as an anticipated increase in demand during the coming years, GSK Biologicals is pursuing licensure of Fluarix in the U.S.
- Trial name
- NCT00197223
- Testing
- Influenza vaccine
- Where
- Czechia
- Volunteers
- 6,213 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
The objective of the study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A.
- Trial name
- NCT00971425
- Testing
- Pandemrix (GSK investigational influenza GSK2340272A vaccine), Fluarix™
- Where
- 6 sites in Germany
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Seasonal Influenza
A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults
The purpose of this study is to measure the safety and the immune response to 3 next-generation influenza vaccine candidates (mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1) compared with influenza vaccine candidate mRNA-1010 controls…
- Trial name
- NCT05827068
- Testing
- mRNA-1011.1, mRNA-1011.2, mRNA-1012.1
- Where
- 22 sites in United States
- Volunteers
- 698 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza, Swine-origin A/H1N1 Influenza
A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly
The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine in adults and the elderly. Primary Objectives: To describe the immunogenicity of the candidate vaccines after a single injection.
- Trial name
- NCT00952276
- Testing
- Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant, Monovalent Subvirion A/H1N1 influenza vaccine, Normal saline solution
- Where
- 15 sites in United States
- Volunteers
- 548 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza
Safety, Tolerability and Pharmacokinetic Study of Multiple Doses of CS-8958
The purpose of this study is to test the safety and tolerability of an investigational multi-dose inhaled flu medication, CS-8958. Study participants will include 16 males and females, aged 18-55 years of age, inclusive.
- Trial name
- NCT00995826
- Testing
- CS-8958
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Biota Scientific Management Pty Ltd
Influenza, Human
A Study to Evaluate the Efficacy and Safety of ZX-7101A Tablets in Adults with Uncomplicated Influenza
The goal of this clinical trial is to compare ZX-7101A in Chinese Adults patients with uncomplicated influenza. The main questions it aims to answer are: The efficacy of ZX-7101A in Chinese Adults patients with uncomplicated…
- Trial name
- NCT05702489
- Testing
- ZX-7101A
- Where
- China
- Volunteers
- 900 people
- Sponsor
- Nanjing Zenshine Pharmaceuticals
Influenza Vaccine
A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of Age
If study subject's legal guardians who decide voluntarily to participate the clinical trial, and sign the Informed Consent Formed, study subjects eligible for participating this trial protocol were assigned to test group or…
- Trial name
- NCT03285997
- Testing
- GC3110A, GCFLU Pre-filled syringe inj.
- Where
- South Korea
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Influenza, Human, Respiratory Syncytial Virus Infections
Evaluation of Performance of the LumiraDx Influenza A/B + RSV Test at POC Testing Sites
A Multicenter Study Conducted to Evaluate the Performance of the LumiraDx Influenza A/B + RSV Test at Point of Care Testing Sites
- Trial name
- INSPIRE (NCT04288921)
- Testing
- Swab
- Where
- 20 sites in United States
- Volunteers
- 525 people
- Sponsor
- LumiraDx UK Limited
Influenza
Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects
This study is designed to evaluate the immunogenicity, safety and tolerability of 2 doses of FLUAD-H5N1 vaccine compared to 2 doses of trivalent, interpandemic FLUAD, each administered 3 weeks apart.
- Trial name
- NCT00434733
- Testing
- Pandemic influenza vaccine
- Where
- Poland
- Volunteers
- 4,400 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza
Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg
The present study will evaluate the efficacy, immunogenicity and safety of one dose of OVX836 influenza vaccine 480μg, after intramuscular administration in healthy subjects aged 18-59 years.
- Trial name
- NCT05569239
- Testing
- OVX836 480µg, Saline Solution
- Where
- 16 sites in Belgium, Finland and 2 more
- Volunteers
- 2,891 people, healthy volunteers welcome
- Sponsor
- Osivax
Avian Influenza
A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age
This Phase 3 study evaluates the safety, immunogenicity and lot-to lot consistency of 3 lots of aH5N1c vaccine for pandemic avian influenza, in approximately 2394 healthy adults ≥18 years of age receiving the vaccine and 797…
- Trial name
- NCT02839330
- Testing
- aH5N1c
- Where
- 26 sites in United States
- Volunteers
- 3,196 people, healthy volunteers welcome
- Sponsor
- Seqirus
Cough
Comparison Between Oxomemazine, Guaifenesin and Potassium Iodate Versus Guaifenesin Monotherapy in Acute Cough Treatment
The purpose of this study is evaluate if efficacy of a combination dose of oxomemazine, guaifenesin and potassium iodate is superior than guaifenesin monotherapy in acute cough treatment.
- Trial name
- NCT01257243
- Testing
- Syrup of oxomemazine, guaifenesin and potassium iodate, Syrup of guaifenesin
- Where
- Brazil
- Volunteers
- 260 people
- Sponsor
- EMS
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults
This trial will assess the immunogenicity and safety of GSK Biologicals' vaccine GSK1557484A, prepared from old concentrated monobulk material, in adults aged 18 to 64 years, when administered up to 5 years following production.
- Trial name
- NCT01416571
- Testing
- Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza
This study will evaluate the efficacy, safety, and pharmacokinetics of baloxavir marboxil in combination with a standard-of-care (SOC) neuraminidase inhibitor (NAI) (i.e., oseltamivir, zanamivir, or peramivir) compared with a…
- Trial name
- NCT03684044
- Testing
- Baloxavir Marboxil
- Where
- 170 sites in United States, Argentina and 26 more
- Volunteers
- 363 people
- Sponsor
- Hoffmann-La Roche
Influenza
Study of a Pandemic Influenza Vaccine in Elderly Participants
The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is one of the leading candidates to cause the next influenza pandemic.
- Trial name
- NCT00376402
- Testing
- H5N1 Pandemic Influenza Vaccine
- Where
- 2 sites in Australia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
A Study to Demonstrate the Efficacy of GSK Biologicals' Influenza Vaccine in Adults
The purpose of this study is to demonstrate the efficacy of GSK Biologicals' influenza vaccine (Fluarix™) administered intramuscularly in adults.
- Trial name
- NCT00363870
- Testing
- Fluarix vaccine
- Where
- 15 sites in Czechia, Finland
- Volunteers
- 7,632 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
The purpose of this study is to evaluate the preventative antiviral activity of CD388, as compared to saline placebo, when administered as a single dose to healthy adult participants in a human viral challenge model of influenza.
- Trial name
- NCT05523089
- Testing
- CD388
- Where
- United Kingdom
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Influenza
FluLaval® Quadrivalent Pregnancy Registry
The purpose of this pregnancy registry study is to detect and describe any abnormal pregnancy outcomes in women intentionally or unintentionally vaccinated with FluLaval Quadrivalent.
- Trial name
- NCT02000466
- Testing
- Data collection
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.